Yang Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Zhou has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Lichen Yin
Soochow University
5 shared publications Ziyin Zhao
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China
3 shared publicationsChenglong Ge
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China
2 shared publicationsChunxian Piao
Department of Bioengineering, College of Engineering, Hanyang University, Korea
1 shared publication- Desheng Cao
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China
1 shared publication - E. Song
Department of Ophthalmology, Lixiang Eye Hospital of Soochow University
1 shared publication
Latest Publications
- 15 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (14) , 3857-3873
Light-programmable, high-drug-loading nanomedicine based on dimeric camptothecin
Light-programmable, high-drug-loading PEG-PLA nanoparticles were developed to co-encapsulate both the photosensitizer (Ce6) and the hypoxia-activatable dimeric camptothecin prodrug (hQ-CPT 2 ) for synergistic antitumor treatment.
- 15 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (14) , 3857-3873
Light-programmable, high-drug-loading nanomedicine based on dimeric camptothecin
Light-programmable, high-drug-loading PEG-PLA nanoparticles were developed to co-encapsulate both the photosensitizer (Ce6) and the hypoxia-activatable dimeric camptothecin prodrug (hQ-CPT 2 ) for synergistic antitumor treatment.
- 30 April 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (11) , 3013-3023
Inflammation-responsive hierarchical delivery of anti-inflammatory siRNA and peptide alleviates cytokine storm in pneumonia
Pulmonary delivery of anti-inflammatory siRNA holds great potential for the management of severe pneumonia. However, conventional siRNA carriers, primarily cationic polymers, struggle to penetrate the mucus barrier, resulting in limited transfection efficiency. Herein, nanocomplexes (NCs) capable of penetrating both the mucus and cytomembrane barriers were developed to deliver TNF-α siRNA (siTNF-α) for effective pneumonia management. To construct the NCs, membrane-penetrating polypeptide (DPP) first condensed siTNF-α and formed a cationic inner core, which was further coated with a charge-reversal polymer (PD) followed by the adsorption of a RAGE-binding peptide (RBP) via electrostatic interactions. The resulting RDDsT NCs exhibited negatively charged surfaces and thus enabled efficient mucus layer penetration after intratracheal administration in lipopolysaccharide (LPS)-induced acute lung injury (ALI) mice. In the slightly acidic microenvironment of inflamed alveolar space, PD underwent charge reversal from negatively charged to positively charged, shedding off to facilitate the intracellular delivery of the DPP/siTNF-α core into alveolar macrophages. Meanwhile, the liberated RBP blocked RAGE–ligand interactions, further down-regulating pro-inflammatory factors. Consequently, the cooperative action of siTNF-α and RBP alleviated inflammation and propelled the recovery of pulmonary functions. This study renders an enlightened strategy to overcome the mucus/cytomembrane barrier against pulmonary siRNA delivery, and holds profound potential for gene/peptide co-therapy against pneumonia.
- 30 April 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (11) , 3013-3023
Inflammation-responsive hierarchical delivery of anti-inflammatory siRNA and peptide alleviates cytokine storm in pneumonia
Pulmonary delivery of anti-inflammatory siRNA holds great potential for the management of severe pneumonia. However, conventional siRNA carriers, primarily cationic polymers, struggle to penetrate the mucus barrier, resulting in limited transfection efficiency. Herein, nanocomplexes (NCs) capable of penetrating both the mucus and cytomembrane barriers were developed to deliver TNF-α siRNA (siTNF-α) for effective pneumonia management. To construct the NCs, membrane-penetrating polypeptide (DPP) first condensed siTNF-α and formed a cationic inner core, which was further coated with a charge-reversal polymer (PD) followed by the adsorption of a RAGE-binding peptide (RBP) via electrostatic interactions. The resulting RDDsT NCs exhibited negatively charged surfaces and thus enabled efficient mucus layer penetration after intratracheal administration in lipopolysaccharide (LPS)-induced acute lung injury (ALI) mice. In the slightly acidic microenvironment of inflamed alveolar space, PD underwent charge reversal from negatively charged to positively charged, shedding off to facilitate the intracellular delivery of the DPP/siTNF-α core into alveolar macrophages. Meanwhile, the liberated RBP blocked RAGE–ligand interactions, further down-regulating pro-inflammatory factors. Consequently, the cooperative action of siTNF-α and RBP alleviated inflammation and propelled the recovery of pulmonary functions. This study renders an enlightened strategy to overcome the mucus/cytomembrane barrier against pulmonary siRNA delivery, and holds profound potential for gene/peptide co-therapy against pneumonia.
- Top Cited PapersOpen Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadj0006
Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadj0006
Top Cited PapersOpen AccessDynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.
- 7 March 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 196, 423-435
Oxygen/siRNA-carrying fluoro-nanosensitizers for radio-immunotherapy sensitization
- 7 March 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 196, 423-435
Oxygen/siRNA-carrying fluoro-nanosensitizers for radio-immunotherapy sensitization
- 5 August 2023
- Published by Springer Nature
- p. 1370-1381
Machine Learning Approach to Examine the Influence of the Community Environment on the Quality of Life of the Elderly
- 5 August 2023
- Published by Springer Nature
- p. 1370-1381
Machine Learning Approach to Examine the Influence of the Community Environment on the Quality of Life of the Elderly
- Open Access
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Cytokine-scavenging nanodecoys reconstruct osteoclast/osteoblast balance toward the treatment of postmenopausal osteoporosis
Biomimetic nanodecoys reconstruct the osteoclast/osteoblast balance to treat postmenopausal osteoporosis.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Open AccessCytokine-scavenging nanodecoys reconstruct osteoclast/osteoblast balance toward the treatment of postmenopausal osteoporosis
Biomimetic nanodecoys reconstruct the osteoclast/osteoblast balance to treat postmenopausal osteoporosis.